![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: NF2 |
Gene summary for NF2 |
![]() |
Gene information | Species | Human | Gene symbol | NF2 | Gene ID | 4771 |
Gene name | neurofibromin 2 | |
Gene Alias | ACN | |
Cytomap | 22q12.2 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | A0A024R1J8 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
4771 | NF2 | P74T-E | Human | Esophagus | ESCC | 2.80e-07 | 2.81e-01 | 0.1479 |
4771 | NF2 | P75T-E | Human | Esophagus | ESCC | 9.61e-08 | 1.90e-01 | 0.1125 |
4771 | NF2 | P76T-E | Human | Esophagus | ESCC | 4.32e-12 | 2.85e-01 | 0.1207 |
4771 | NF2 | P79T-E | Human | Esophagus | ESCC | 4.32e-17 | 3.03e-01 | 0.1154 |
4771 | NF2 | P80T-E | Human | Esophagus | ESCC | 1.78e-06 | 2.81e-01 | 0.155 |
4771 | NF2 | P82T-E | Human | Esophagus | ESCC | 4.61e-02 | 2.04e-01 | 0.1072 |
4771 | NF2 | P83T-E | Human | Esophagus | ESCC | 1.07e-11 | 4.49e-01 | 0.1738 |
4771 | NF2 | P89T-E | Human | Esophagus | ESCC | 1.07e-09 | 5.64e-01 | 0.1752 |
4771 | NF2 | P91T-E | Human | Esophagus | ESCC | 3.59e-11 | 9.59e-01 | 0.1828 |
4771 | NF2 | P107T-E | Human | Esophagus | ESCC | 4.41e-18 | 3.34e-01 | 0.171 |
4771 | NF2 | P127T-E | Human | Esophagus | ESCC | 5.30e-03 | 8.00e-02 | 0.0826 |
4771 | NF2 | P128T-E | Human | Esophagus | ESCC | 8.31e-10 | 4.28e-01 | 0.1241 |
4771 | NF2 | P130T-E | Human | Esophagus | ESCC | 1.51e-22 | 4.93e-01 | 0.1676 |
4771 | NF2 | C04 | Human | Oral cavity | OSCC | 1.16e-09 | 5.55e-01 | 0.2633 |
4771 | NF2 | C21 | Human | Oral cavity | OSCC | 7.42e-18 | 6.22e-01 | 0.2678 |
4771 | NF2 | C30 | Human | Oral cavity | OSCC | 1.32e-15 | 7.59e-01 | 0.3055 |
4771 | NF2 | C43 | Human | Oral cavity | OSCC | 8.58e-09 | 2.26e-01 | 0.1704 |
4771 | NF2 | C46 | Human | Oral cavity | OSCC | 1.11e-04 | 1.71e-01 | 0.1673 |
4771 | NF2 | C51 | Human | Oral cavity | OSCC | 5.76e-05 | 4.84e-01 | 0.2674 |
4771 | NF2 | C08 | Human | Oral cavity | OSCC | 1.06e-05 | 1.65e-01 | 0.1919 |
Page: 1 2 3 4 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00508219 | Breast | Precancer | protein stabilization | 29/1080 | 191/18723 | 1.67e-06 | 6.08e-05 | 29 |
GO:00316479 | Breast | Precancer | regulation of protein stability | 38/1080 | 298/18723 | 3.73e-06 | 1.19e-04 | 38 |
GO:003164714 | Breast | IDC | regulation of protein stability | 50/1434 | 298/18723 | 1.14e-07 | 6.57e-06 | 50 |
GO:005082114 | Breast | IDC | protein stabilization | 35/1434 | 191/18723 | 1.12e-06 | 5.04e-05 | 35 |
GO:00512589 | Breast | IDC | protein polymerization | 38/1434 | 297/18723 | 1.26e-03 | 1.34e-02 | 38 |
GO:00330445 | Breast | IDC | regulation of chromosome organization | 26/1434 | 187/18723 | 2.22e-03 | 2.06e-02 | 26 |
GO:00073465 | Breast | IDC | regulation of mitotic cell cycle | 51/1434 | 457/18723 | 4.30e-03 | 3.35e-02 | 51 |
GO:003164724 | Breast | DCIS | regulation of protein stability | 51/1390 | 298/18723 | 1.63e-08 | 1.15e-06 | 51 |
GO:005082124 | Breast | DCIS | protein stabilization | 36/1390 | 191/18723 | 1.82e-07 | 9.14e-06 | 36 |
GO:005125814 | Breast | DCIS | protein polymerization | 39/1390 | 297/18723 | 3.64e-04 | 5.15e-03 | 39 |
GO:000734612 | Breast | DCIS | regulation of mitotic cell cycle | 52/1390 | 457/18723 | 1.38e-03 | 1.43e-02 | 52 |
GO:003304412 | Breast | DCIS | regulation of chromosome organization | 26/1390 | 187/18723 | 1.44e-03 | 1.47e-02 | 26 |
GO:00447724 | Breast | DCIS | mitotic cell cycle phase transition | 46/1390 | 424/18723 | 6.16e-03 | 4.39e-02 | 46 |
GO:004217610 | Cervix | CC | regulation of protein catabolic process | 104/2311 | 391/18723 | 9.39e-15 | 9.36e-12 | 104 |
GO:004586210 | Cervix | CC | positive regulation of proteolysis | 95/2311 | 372/18723 | 1.84e-12 | 6.86e-10 | 95 |
GO:190336210 | Cervix | CC | regulation of cellular protein catabolic process | 72/2311 | 255/18723 | 5.98e-12 | 2.10e-09 | 72 |
GO:004573210 | Cervix | CC | positive regulation of protein catabolic process | 65/2311 | 231/18723 | 7.44e-11 | 1.39e-08 | 65 |
GO:001049810 | Cervix | CC | proteasomal protein catabolic process | 111/2311 | 490/18723 | 8.98e-11 | 1.58e-08 | 111 |
GO:000989610 | Cervix | CC | positive regulation of catabolic process | 109/2311 | 492/18723 | 5.26e-10 | 6.99e-08 | 109 |
GO:190305010 | Cervix | CC | regulation of proteolysis involved in cellular protein catabolic process | 60/2311 | 221/18723 | 1.82e-09 | 1.98e-07 | 60 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa04530211 | Esophagus | ESCC | Tight junction | 105/4205 | 169/8465 | 6.73e-04 | 2.23e-03 | 1.14e-03 | 105 |
hsa0439018 | Esophagus | ESCC | Hippo signaling pathway | 92/4205 | 157/8465 | 1.46e-02 | 3.31e-02 | 1.69e-02 | 92 |
hsa04530310 | Esophagus | ESCC | Tight junction | 105/4205 | 169/8465 | 6.73e-04 | 2.23e-03 | 1.14e-03 | 105 |
hsa0439019 | Esophagus | ESCC | Hippo signaling pathway | 92/4205 | 157/8465 | 1.46e-02 | 3.31e-02 | 1.69e-02 | 92 |
hsa0453030 | Oral cavity | OSCC | Tight junction | 102/3704 | 169/8465 | 8.68e-06 | 3.93e-05 | 2.00e-05 | 102 |
hsa0439016 | Oral cavity | OSCC | Hippo signaling pathway | 86/3704 | 157/8465 | 3.30e-03 | 8.24e-03 | 4.20e-03 | 86 |
hsa04530114 | Oral cavity | OSCC | Tight junction | 102/3704 | 169/8465 | 8.68e-06 | 3.93e-05 | 2.00e-05 | 102 |
hsa0439017 | Oral cavity | OSCC | Hippo signaling pathway | 86/3704 | 157/8465 | 3.30e-03 | 8.24e-03 | 4.20e-03 | 86 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NF2 | SNV | Missense_Mutation | c.645N>C | p.Glu215Asp | p.E215D | P35240 | protein_coding | tolerated(0.61) | benign(0.003) | TCGA-BH-A0C7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR | |
NF2 | SNV | Missense_Mutation | c.17N>T | p.Ala6Val | p.A6V | P35240 | protein_coding | deleterious_low_confidence(0.01) | benign(0.023) | TCGA-C5-A7CO-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | SD | |
NF2 | SNV | Missense_Mutation | rs74315503 | c.1387N>A | p.Glu463Lys | p.E463K | P35240 | protein_coding | tolerated(0.49) | benign(0.311) | TCGA-C5-A8XK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
NF2 | SNV | Missense_Mutation | rs765386271 | c.1672N>G | p.Leu558Val | p.L558V | P35240 | protein_coding | tolerated(0.08) | possibly_damaging(0.528) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
NF2 | SNV | Missense_Mutation | novel | c.746N>A | p.Arg249Lys | p.R249K | P35240 | protein_coding | tolerated(1) | benign(0.003) | TCGA-VS-A94Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
NF2 | SNV | Missense_Mutation | rs776109136 | c.1391N>T | p.Ala464Val | p.A464V | P35240 | protein_coding | deleterious(0.01) | possibly_damaging(0.798) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
NF2 | SNV | Missense_Mutation | c.813N>G | p.Phe271Leu | p.F271L | P35240 | protein_coding | tolerated(0.15) | benign(0.411) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
NF2 | SNV | Missense_Mutation | c.1075A>T | p.Arg359Trp | p.R359W | P35240 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AU-6004-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
NF2 | SNV | Missense_Mutation | novel | c.275N>C | p.Val92Ala | p.V92A | P35240 | protein_coding | tolerated(0.28) | benign(0.396) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
NF2 | SNV | Missense_Mutation | novel | c.369N>T | p.Lys123Asn | p.K123N | P35240 | protein_coding | deleterious(0.02) | probably_damaging(0.918) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4771 | NF2 | CLINICALLY ACTIONABLE, TUMOR SUPPRESSOR, DRUG RESISTANCE, KINASE | SELUMETINIB | SELUMETINIB | 26359368 | |
4771 | NF2 | CLINICALLY ACTIONABLE, TUMOR SUPPRESSOR, DRUG RESISTANCE, KINASE | EVEROLIMUS | EVEROLIMUS | 25567352 | |
4771 | NF2 | CLINICALLY ACTIONABLE, TUMOR SUPPRESSOR, DRUG RESISTANCE, KINASE | TEMSIROLIMUS | TEMSIROLIMUS | 25878190 | |
4771 | NF2 | CLINICALLY ACTIONABLE, TUMOR SUPPRESSOR, DRUG RESISTANCE, KINASE | CISPLATIN | CISPLATIN | 25798586 | |
4771 | NF2 | CLINICALLY ACTIONABLE, TUMOR SUPPRESSOR, DRUG RESISTANCE, KINASE | CARBOPLATIN | CARBOPLATIN | 25798586 |
Page: 1 |